Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy

Kidney International Reports 2026 Open access

Read full text
Authors: Yousra Cheddadi, Mounir El Maï, Vesna Brglez, Sarah Nahon Carzo, Marion Crémoni, Maxime Teisseyre, Barbara Seitz‐Polski
DOI: 10.1016/j.ekir.2026.106365
Cited by: 1
References: 10

Abstract

Membranous nephropathy (MN) is an autoimmune kidney disease and the leading cause of nephrotic syndrome in adults. B-cells play a pivotal role in the pathogenesis of MN through the generation of autoantibodies. Approximately 70% of patients with MN have autoantibodies targeting the phospholipase A2 receptor 1 (PLA2R1).1 The discovery of these autoantibodies has transformed the management of MN, promoting the use of targeted B-cell-depleting therapies.2 Rituximab selectively depletes B-cells and has become a cornerstone of treatment.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Publisher
Elsevier BV
Volume
11
Issue
5
Pages
106365–106365
Publication date
19 February 2026
Language
EN